The ESMO Congress recently took place in Madrid, and presidential symposium sessions highlighted upcoming new standards of care based on several groundbreaking studies. These present a potential change to clinical management for patients with urothelial cancer, lung cancer and colorectal cancer. The studies reviewed the combination of pembrolizumab and enfortumab vedotin, showing remarkable efficacy in patients with urothelial cancer. New treatment with nivolumab and chemotherapy was proposed for non-small cell lung cancer. Additionally, the combination of sotorasib and panitumumab presented a new standard care for those with colorectal cancer. Researchers aim to address how to make these solutions more affordable and improve patient care.
Source link
‘Monumental’ and ‘highly meaningful’ advances across solid tumors highlight ESMO program
